Financial GuidanceY-mAbs provided 2024 financial guidance with expected DANYELZA revenues of $95-100M, reflecting a strong sales outlook for the drug.
Stock Rating And Target PriceAnalyst reiterates a Buy rating and raises the 12-month price target to $22, signaling confidence in the company's future performance.
Technological AdvancementThe SADA technology platform is recognized for its potential to revolutionize radioimmunotherapy applications in oncology, offering a new growth avenue for Y-mAbs.